7<*:=+W0_|Q7J]9'X;|#L_TZ)@!20E
SYSTEM PROCESSING...
7<*:=+W0_|Q7J]9'X;|#L_TZ)@!20E
SYSTEM PROCESSING...
Posted: 2025-06-25 09:21:24 UTC
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
This article contains some claims that are falsified. While not everything in the article is false, please proceed with extreme caution and verify any critical information independently.
Status
Last Updated
2025-06-25 09:21:42 UTC
Verified By
Rollup News
Researchers mapped post-COVID and ME/CFS patients into three biological clusters using neuroimmune markers: mitochondrial stress, non-inflammatory, and neuroinflammatory. This explains mixed trial results and suggests personalized therapies.
Identified three distinct biological subtypes in post-COVID and ME/CFS patients.
Highlights the need for personalized therapies based on these subtypes.
Explains the variability in clinical trial outcomes due to patient heterogeneity.
Mixed results in clinical trials.
Understanding the heterogeneity of post-COVID and ME/CFS patients.
Developing personalized therapies for different subtypes.